Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 422 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort B: placebo Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05704738
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 17 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
98
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Early Phase 1 Interventional

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

NCT06109948
View directory record Official record
Conditions
Healthy, Late Onset Pompe Disease
Interventions
ABX1100 injection for IV infusion, Placebo injection for IV infusion
Drug
Lead sponsor
Aro Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Orange, California • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

NCT06026397
View directory record Official record
Conditions
Chemotherapy-induced Diarrhea
Interventions
SK10, Placebo
Drug
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

NCT01910571
View directory record Official record
Conditions
Healthy
Interventions
P7435, Placebo
Drug · Other
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

NCT04044339
View directory record Official record
Conditions
Healthy
Interventions
TD-5202, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 3, 2026, 3:46 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

NCT07839871
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 17 Years
Enrollment
920 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
South Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

NCT05891236
View directory record Official record
Conditions
Malaria
Interventions
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Biological · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 3, 2026, 3:46 AM EDT
Recruiting Phase 1 Interventional

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818
View directory record Official record
Conditions
Graves Disease
Interventions
MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
Biological
Lead sponsor
Merida Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 3, 2026, 3:46 AM EDT
Terminated Phase 2 Interventional

Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT03547206
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B, Placebo Cohort B
Drug · Other
Lead sponsor
Regenera Pharma Ltd
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 3, 2026, 3:46 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

NCT02106338
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Placebo, CRS3123
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

NCT03890302
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
FB704A, Placebo
Drug
Lead sponsor
Fountain Biopharma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
LY3202626, Placebo (Part A, B, C), Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

NCT04643067
View directory record Official record
Conditions
SLE; Drug
Interventions
KPG-818 low dose in phase 1b, KPG-818 mid dose in phase 1b, KPG-818 high dose in phase 1b, KPG-818 ultra-high dose in phase 1b, KPG-818 low dose in phase 2a, KPG-818 mid dose in phase 2a, KPG-818 high dose in phase 2a, KPG-818 Placebo in phase 2a
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234
View directory record Official record
Conditions
Kidney Disease
Interventions
GSK4771261, Placebo matching GSK4771261
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
25 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 3, 2026, 3:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067
View directory record Official record
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 3, 2026, 3:46 AM EDT